BidaskClub upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a sell rating to a hold rating in a report issued on Thursday morning.

Several other research firms have also recently commented on OXFD. ValuEngine raised Oxford Immunotec Global from a hold rating to a buy rating in a report on Wednesday, September 12th. Zacks Investment Research raised Oxford Immunotec Global from a hold rating to a buy rating and set a $16.00 price target for the company in a report on Friday, August 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of Buy and a consensus price target of $17.80.

Shares of NASDAQ:OXFD traded down $0.52 during midday trading on Thursday, hitting $15.85. The company had a trading volume of 6,273 shares, compared to its average volume of 244,124. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.86 and a current ratio of 5.39. The stock has a market cap of $440.93 million, a PE ratio of -11.96 and a beta of -0.21.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, July 31st. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). Oxford Immunotec Global had a negative return on equity of 39.85% and a negative net margin of 23.41%. The firm had revenue of $29.32 million during the quarter, compared to analysts’ expectations of $28.58 million. During the same quarter last year, the firm earned ($0.74) earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, analysts predict that Oxford Immunotec Global will post -0.95 earnings per share for the current fiscal year.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $13.15, for a total transaction of $39,450.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Wrighton-Smith sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $16.71, for a total value of $334,200.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,100 shares of company stock valued at $2,557,612. 6.61% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its stake in Oxford Immunotec Global by 19.7% during the second quarter. Russell Investments Group Ltd. now owns 97,445 shares of the company’s stock worth $1,257,000 after acquiring an additional 16,070 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Oxford Immunotec Global in the second quarter valued at $132,000. Spark Investment Management LLC grew its stake in shares of Oxford Immunotec Global by 45.1% in the second quarter. Spark Investment Management LLC now owns 144,100 shares of the company’s stock valued at $1,857,000 after buying an additional 44,800 shares in the last quarter. Penn Capital Management Co. Inc. grew its stake in shares of Oxford Immunotec Global by 20.4% in the second quarter. Penn Capital Management Co. Inc. now owns 257,026 shares of the company’s stock valued at $3,313,000 after buying an additional 43,477 shares in the last quarter. Finally, Granahan Investment Management Inc. MA grew its stake in shares of Oxford Immunotec Global by 9.1% in the second quarter. Granahan Investment Management Inc. MA now owns 565,332 shares of the company’s stock valued at $7,287,000 after buying an additional 47,159 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Story: What is a stock split?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.